Bis-<3-methyl-pyrazol-5-on-4-yl>-methan | 332045-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: Bis-<3-methyl-pyrazol-5-on-4-yl>-methan
• 英文别名: 4,4'-methylene-bis(3-methyl-2-pyrazolin-5-one)；5,5'-dimethyl-1,2,1',2'-tetrahydro-4,4'-methanediyl-bis-pyrazol-3-one；4,4'-methanediylbis(5-methyl-2,4-dihydro-3H-pyrazol-3-one)；3-methyl-4-[(3-methyl-5-oxo-1,4-dihydropyrazol-4-yl)methyl]-1,4-dihydropyrazol-5-one
• CAS: 332045-13-3
• 化学式: C₉H₁₂N₄O₂
• 分子量: 208.22
• InChiKey: QMRQUTQGAUCBCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  82.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Bis-<3-methyl-pyrazol-5-on-4-yl>-methan 、 cobalt(II) chloride 以 乙醇 为溶剂， 生成 bis(4,4'-methylene-bis(3-methyl-2-pyrazolin-5-one))cobalt(II) chloride
  参考文献：
  名称：

  Nayak; Das; Mahapatra, Journal of the Indian Chemical Society, 1981, vol. 58, # 4, p. 347 - 349

  摘要：

  DOI：

文献信息

• Chroman derivatives
  申请人：Wang Bing

  公开号：US20050065150A1

  公开（公告）日：2005-03-24

  The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

  本发明涉及新型的色甘醇衍生物、立体异构体和公认的药物盐，其化学式为I式，其中取代基如规范中所定义。它们可用于治疗通过脂氧合酶介导的疾病，如免疫性疾病、呼吸系统疾病和心血管疾病，以及神经退行性疾病和/或线粒体疾病的治疗。它们还可用于制造用于治疗这些疾病的药物制剂。
• CHROMAN DERIVATIVES
  申请人：WANG Bing

  公开号：US20120088783A1

  公开（公告）日：2012-04-12

  The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

  本发明涉及新型的色甘醇衍生物、立体异构体及其在药学上可接受的盐，其化学式为I，其中置换基如规范中所定义。它们可用于治疗通过脂氧合酶介导的疾病，如免疫性疾病、呼吸系统疾病和心血管疾病，以及神经退行性疾病和/或线粒体疾病的治疗。它们也可用于制造用于治疗此类疾病的药物制剂。
• US7514461B2
  申请人：——

  公开号：US7514461B2

  公开（公告）日：2009-04-07
• US8044097B2
  申请人：——

  公开号：US8044097B2

  公开（公告）日：2011-10-25
• US8791155B2
  申请人：——

  公开号：US8791155B2

  公开（公告）日：2014-07-29